Shots:

• The companies collaborated to evaluate IMU-838 (DHODH inhibitors) + NHC (nucleoside analogues) to treat patients with viral infections including COVID-19 and Influenza
• The preclinical research showed that IMU-838 strongly synergizes with selected nucleoside analogues to inhibit SARS-CoV-2 replication in vitro. In vitro test system- IMU-838 & NHC alone showed 99.9% & 99% reduction in viral RNA at concentrations of 5μM & 100 nM
• The enrollment of the first patient in the P-II CALLIPER trial of IMU-838 for MS is expected in Sept’21 & for the P-III ENSURE program in Q4’21. Additionally- the P-II results of IMU-838 in UC is expected to be available in Q2’22

Click here  | Ref: Immunic | Image: PR Newswire